A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

NCT02956486 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2212

Enrollment

INDUSTRY

Sponsor class

Stopped Due to an unfavorable risk-benefit ratio including no evidence of potential efficacy, and the adverse event profile of E2609 being worse than placebo.

Conditions

Alzheimer's Disease

Interventions

DRUG: Elenbecestat
DRUG: Placebo

Sponsor

Eisai Co., Ltd.

Collaborators

[object Object]